A Data-Driven Case for Interdisciplinary Pain Care, with a New York State Lens. One in four American adults now lives with chronic pain, reflecting post-pandemic acceleration that the clinical community is only beginning to reckon with. The economic burden exceeds the combined costs of diabetes, cardiovascular disease, and cancer. The path forward will require implementation infrastructure for multidisciplinary care.
For decades, the clinical response to chronic pain defaulted to opioid pharmacotherapy. We know how that story ends. The 2016 CDC prescribing guidelines constrained opioid access but offered clinicians few viable alternatives. That's the gap the NIH Helping to End Addiction Long-term (HEAL) Initiative was built to close.
The success rate of novel pain drugs making it from Phase I trials to FDA approval is 0.7% vs the 6.5% average across all other therapeutic areas is staggering. For two decades, the pharmaceutical pipeline for chronic pain has been collapsing—and we're still building our treatment models around it. The annual cost of the 50 million American adults living with chronic daily pain is $560-$635 billion—more than heart disease, cancer, and diabetes combined. If the traditional pharmacological approach keeps failing, why aren't the approaches that ARE working getting the investment, the coverage, and the clinical priority they deserve?
The U.S. has only one board-certified Pain Medicine specialist for every 28,500 people with chronic pain and 80% of rural communities are classified as medically underserved. If patients can’t come to us, how do we bring care to them?
Copyright © 2026
